Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

141. The 2012 Hormone Therapy Position Statement of The North American Menopause Society

The 2012 Hormone Therapy Position Statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 19, No. 3, pp. 257/271 DOI: 10.1097/gme.0b013e31824b970a * 2012 by The North American Menopause Society POSITION STATEMENT The 2012 Hormone Therapy Position Statement of The North American Menopause Society Abstract Objective: This position statement aimed to update the evidence-based position statement published by The North American Menopause (...) Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position statement further distinguishes the emerging differences in the therapeutic benefit-risk ratio between estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) at various ages and time intervals since menopause onset. Methods: An Advisory Panel of expert clinicians and researchers in the field of women’s health was enlisted to review the 2010 NAMS position statement

2012 The North American Menopause Society

142. Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations

Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations. Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services (...) Task Force Recommendations. Nelson HD, Walker M, Zakher B, Mitchell J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations

2012 Health Technology Assessment (HTA) Database.

143. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of secondary plus tertiary prevention of osteoporosis by identifying post-menopausal women who were at increased risk of fractures, compared with tertiary prevention alone. The authors concluded that both prevention strategies were cost-effective compared with no prevention. Secondary plus tertiary prevention was more effective and more

2012 NHS Economic Evaluation Database.

144. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. (PubMed)

Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. To use changes in heart disease mortality rates with age to investigate the plausibility of attributing women's lower heart disease mortality than men to the protective effects of premenopausal sex hormones.Modelling study of longitudinal mortality data with models assuming (i) a linear association between mortality rates and age (absolute mortality (...) data.Proportional age related changes in ischaemic heart disease mortality, suggesting a loss of reparative reserve, fit longitudinal mortality data from England, Wales, and the United States better than absolute age related changes in mortality. Acceleration in male heart disease mortality at younger ages could explain sex differences rather than any menopausal changes in women.

Full Text available with Trip Pro

2011 BMJ

145. Abnormal vaginal bleeding in pre-, peri- and post-menopausal women. A diagnostic guide for general practitioners and gynaecologists

Abnormal vaginal bleeding in pre-, peri- and post-menopausal women. A diagnostic guide for general practitioners and gynaecologists GP refer to GynaecoloGist refer to GynaecoloGical oncoloGist History (including menstruation—any changes, irregularities), physical examination (including speculum and pelvic examination) and identify risk factors Exclude pregnancy Exclude cervical pathology: pap smear and screen for chlamydia. Colposcopy recommended for post coital bleeding Full blood count (...) includes the endometrial thickness. The GP should also indicate on the request form the menopausal status of the patient (eg. pre, peri or post). Endometrial Biopsy • Invasive procedures should be undertaken (when possible) by the relevant specialist (gynaecologist, gynaecological oncologist). • If insufficient material is obtained for a histological diagnosis, no further investigation is required in the absence of ongoing bleeding unless the woman has an endometrial thickness over 12mm for pre

2011 Clinical Practice Guidelines Portal

146. Exercise for vasomotor menopausal symptoms. (PubMed)

Exercise for vasomotor menopausal symptoms. Evidence suggests that many perimenopausal and early postmenopausal women will experience menopause symptoms, hot flushes being the most common. Symptoms caused by fluctuating levels of oestrogen may be alleviated by HRT but there has been a marked global decline in its use due to concerns about the risks and benefits of HRT; consequently many women are now seeking alternatives. As large numbers of women are choosing not to take HRT (...) , it is increasingly important to identify evidence based lifestyle modification interventions that have potential to reduce vasomotor menopausal symptoms.To examine the effectiveness of any type of exercise intervention in the management of vasomotor menopausal symptoms (hot flushes and night sweats) in perimenopausal and postmenopausal women.Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials (RCTs): Cochrane Menstrual Disorders and Subfertility

2011 Cochrane

147. Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density

Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density – TheNNTTheNNT Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or With Very Low Bone Density 100 for hip fracture In Summary, for those who took the bisphosphonates: Benefits in NNT 94% saw no benefit after 3 years of treatment 5% avoided

2011 theNNT

148. Bishosphonates for Fracture Prevention in Post-Menopausal Women Without Prior Fractures

Bishosphonates for Fracture Prevention in Post-Menopausal Women Without Prior Fractures Bisphosphonates for Fracture Prevention in Post-Menopausal Women Without Prior Fractures – TheNNTTheNNT Bisphosphonates for Fracture Prevention in Post-Menopausal Women Without Prior Fractures No benefit found In Summary, for those who took the bisphosphonates: Benefits in NNT 100% saw no benefit after 3 years of treatment None were helped (fracture prevented after 3 years of medicine) Harms in NNT A small

2011 theNNT

149. Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial (PubMed)

Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial FM is a condition that preferentially affects women. Sex hormones, and in particular oestrogens, have been shown to affect pain processing and pain sensitivity, and oestrogen deficit has been considered a potentially promoting factor for FM. However, the effects of oestrogen treatment (...) in patients suffering from FM have not been studied. Here, we examined the effect of transdermal oestrogen substitution treatment on experimental as well as self-estimated pain in women suffering from FM.Twenty-nine post-menopausal women were randomized to either 8 weeks of treatment with transdermal 17β-oestradiol (50 µg/day) or placebo according to a double-blind protocol. A self-estimation of pain, a set of quantitative sensory tests measuring thresholds to temperature, thermal pain, cold pain

Full Text available with Trip Pro

2011 EvidenceUpdates

150. WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. (PubMed)

WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. hMG and recombinant FSH, have both been used successfully for controlled ovarian hyperstimulation in in vitro fertilization and embryo transfer (IVF-ET).To compare the effectiveness of hMG with rFSH in ovarian stimulation protocols in IVF or ICSI treatment cycles.We searched the Cochrane Menstrual Disorders and Subfertility Group trials register

2011 Cochrane

151. AACE Medical Guidelines for Clinical Practice for Diagnosis and Treatment of Menopause

AACE Medical Guidelines for Clinical Practice for Diagnosis and Treatment of Menopause 1 AACE Guidelines Neil F. Goodman, MD, FACE; Rhoda H. Cobin, MD, MACE; Samara Beth Ginzburg, MD; Ira A. Katz, MD, FACE; Dwain E. Woode, MD American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice are systematically developed statements to assist health care professionals in medical decision making for specific clinical conditions but are in no way a substitute for a medical (...) for, their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. Copyright © 2011 AACE.2 AACE Menopause Guidelines Revision Task Force Cochairpersons Neil F . Goodman, MD, F ACE Rhoda H. Cobin, MD, MACE Task Force Members Samara Beth Ginzburg, MD Ira A. Katz, MD, F ACE Dwain E. Woode, MD Reviewers Pauline M. Camacho, MD, F ACE JoAnn E

2011 American Association of Clinical Endocrinologists

152. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. (PubMed)

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. Concerns regarding the risks associated with estrogen and progesterone to manage menopausal symptoms have resulted in its declining use and increased interest in nonhormonal treatments with demonstrated efficacy for hot flashes.To determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother (...) of menopausal hot flashes.A multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel group trial that enrolled 205 women (95 African American; 102 white; 8 other) between July 2009 and June 2010.Women received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks.Primary outcomes were the frequency and severity of hot flashes assessed by prospective daily diaries at weeks 4 and 8. Secondary outcomes were hot flash bother, recorded on daily diaries, and clinical improvement

Full Text available with Trip Pro

2011 JAMA

153. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. (PubMed)

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available.To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin (...) -releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.The PROMISE-GIM6 (Prevention of Menopause Induced by Chemotherapy: A Study in Early Breast Cancer Patients-Gruppo Italiano Mammella 6) study, a parallel, randomized, open-label, phase 3 superiority trial, was conducted at 16 sites in Italy and enrolled 281 patients between October 2003 and January 2008. The patients were

Full Text available with Trip Pro

2011 JAMA

154. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L CRD summary The authors concluded that indirect treatment comparisons (...) indicated teriparatide, zoledronic acid and denosumab had the highest probabilities of being most efficacious for non-vertebral and vertebral fractures. In the absence of direct comparisons, the evidence presented may be the best available. However, the authors' conclusions should be considered tentative given limitations of the evidence and synthesis. Authors' objectives To compare the efficacy of nine osteoporosis medications for reducing fractures in post-menopausal women. Searching Seven databases

Full Text available with Trip Pro

2011 DARE.

155. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cotte FE, De Pouvourville G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of osteoporosis treatment with oral bisphosphonates focusing on the issue of poor persistence in post-menopausal women. The authors concluded that improving persistence with oral bisphosphonate was likely to improve health benefits and reduce costs compared to current levels of treatment adherence

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

156. Odanacatib for post-menopausal osteoporosis ? first or second line

Odanacatib for post-menopausal osteoporosis ? first or second line Odanacatib for post-menopausal osteoporosis – first or second line Odanacatib for post-menopausal osteoporosis – first or second line NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Odanacatib for post-menopausal osteoporosis – first or second line. Birmingham

2011 Health Technology Assessment (HTA) Database.

157. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society

Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 17, No. 1, pp. 23/24 DOI: 10.1097/gme.0b013e3181cdd4a7 * 2010 by The North American Menopause Society 5 Text printed on acid-free paper NAMS continuing medical education activity Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society This position (...) statement, which begins on page 25, has been designatedacontinuingmedicaleducation(CME)activityfrom The North AmericanMenopause Society(NAMS). GOAL To demonstrate an increase in, or affirmation of, current knowledge regarding the management of osteoporosis in postmenopausal women. LEARNING OBJECTIVES After reading this position statement, participants should be able to: & Describe the effect of menopause and aging on bone health. & Identify risk factors that contribute to fracture risk. & Discuss

2010 The North American Menopause Society

158. Alternatives to HRT for the Management of Symptoms of the Menopause

Alternatives to HRT for the Management of Symptoms of the Menopause Alternatives to HRT for the Management of Symptoms of the Menopause Scientific Impact Paper No. 6 September 2010Alternatives to HRT for the Management of Symptoms of the Menopause This is the second edition of this Opinion Paper, which was originally published in 2006. 1. Background Despite recent encouraging data regarding the safety of traditional hormone replacement therapy (HRT), women and their primary care practitioners (...) of the publication from four years ago, aims to provide the reader with state-of-the-art knowledge on alternatives to HRT for the management of menopausal symptoms. 2. Lifestyle measures There is some evidence that women who are more active tend to suffer less from the symptoms of the menopause. 1 However, evidence from randomised controlled trials concerning the effects of aerobic exercise on vasomotor and other menopausal symptoms is limited. 2 The evidence suggests that aerobic exercise can improve

2010 Royal College of Obstetricians and Gynaecologists

159. [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women]

[Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Analisis coste-utilidad de los tratamientos farmacologicos para la prevencion de fracturas en mujeres con osteoporosis en Espana [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Analisis coste-utilidad de los tratamientos farmacologicos para la prevencion de fracturas en (...) mujeres con osteoporosis en Espana [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Imaz I, Rubio B, Lopez-Delgado ME, Amate JM, Gomez-Pajuelo P, Gonzalez-Enriquez J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Imaz I, Rubio B, Lopez-Delgado ME, Amate JM

2010 Health Technology Assessment (HTA) Database.

160. Evaluation of intervention research in weight reduction in post menopausal women

Evaluation of intervention research in weight reduction in post menopausal women Evaluation of intervention research in weight reduction in post menopausal women Evaluation of intervention research in weight reduction in post menopausal women Al Zadjali M, Keller C, Larkey LK, Albertini L CRD summary The review found that exercise when combined with hypocaloric diet or meal replacement therapy may reduce body weight and fat and improve insulin sensitivity, glycaemic control and cardio (...) approaches that addressed lifestyle behaviours and employed a combination of diet and exercise strategies. Funding Not stated. Bibliographic details Al Zadjali M, Keller C, Larkey LK, Albertini L. Evaluation of intervention research in weight reduction in post menopausal women. Geriatric Nursing 2010; 31(6): 419-434 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Evidence-Based Nursing; Female; Humans; Postmenopause; Weight Loss AccessionNumber 12011001797 Date

2010 DARE.